{"id":"ethyl-epa-miraxion","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Fishy aftertaste"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ethyl-EPA is a highly purified, prescription-grade omega-3 fatty acid (EPA ethyl ester) that works by increasing circulating EPA levels to reduce triglyceride synthesis in the liver and promote triglyceride clearance. It may also have anti-inflammatory and cardioprotective effects through modulation of lipid mediators and reduction of systemic inflammation.","oneSentence":"Ethyl-EPA is an ethyl ester of eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism through omega-3 fatty acid supplementation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:50.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia (elevated triglycerides)"},{"name":"Cardiovascular risk reduction in patients with elevated triglycerides"}]},"trialDetails":[{"nctId":"NCT02859129","phase":"PHASE1","title":"Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09","conditions":"Hypertriglyceridemia","enrollment":114},{"nctId":"NCT00146211","phase":"PHASE3","title":"TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease","status":"COMPLETED","sponsor":"Amarin Neuroscience Ltd","startDate":"2005-09","conditions":"Huntington Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ethyl-EPA (Miraxion™)","genericName":"Ethyl-EPA (Miraxion™)","companyName":"Amarin Neuroscience Ltd","companyId":"amarin-neuroscience-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ethyl-EPA is an ethyl ester of eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism through omega-3 fatty acid supplementation. Used for Hypertriglyceridemia (elevated triglycerides), Cardiovascular risk reduction in patients with elevated triglycerides.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}